Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.
You may also be interested in...
If the USPSTF recommendations are finalized, most insurers would need to reimburse Exact Sciences’ US FDA-approved at-home stool DNA test for colorectal cancer and encourage doctors to prescribe more at-home testing.
Nano-X Imaging is on a mission to disrupt the market for X-ray imaging equipment by offering a low-cost medical imaging service to untapped markets through a network of equipment dotted around the world. However, some shareholders are claiming the company mislead investors.
The test measures the relative level of antibodies, which could aid vaccine rollout.